AN2 Therapeutics

Three clinical-stage programs.

A focus on diseases with acute needs.

New frontiers in chemistry.

We’re unlocking boron’s promise for patients.

Discovering boron-based medicines targeting the critical gaps in treatment

Explore our
pipeline

Harnessing the unique properties of boron to unlock new therapeutic possibilities

Learn about our
boron-based science

A team focused on changing the course of diseases and making an impact on the world

See our culture
and careers

News

August 31, 2026
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Read More
August 24, 2026
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
Read More
August 11, 2026
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
Read More
Previous Previous